AbbVie is close to acquiring Apogee Therapeutics for $10.9 billion in cash. Apogee is developing a long-acting drug for atopic dermatitis that blocks the IL-13 protein causing eczema. The drug is expected to enter Phase 3 trials later this year, potentially offering a new treatment option for eczema patients. This acquisition could strengthen AbbVie's position in dermatology treatments.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
